Form 8.3 - AGI Therapeutics plc (2861V)
10 January 2012 - 9:58PM
UK Regulatory
TIDMAGI
RNS Number : 2861V
AGI Therapeutics plc
10 January 2012
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER
PANEL ACT, 1997, TAKEOVER RULES, 2007 (AS AMENDED)
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT
SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
================================================================
Name of person dealing Paul Johnson
(Note 1)
============================ ==================================
Company dealt in AGI Therapeutics plc
============================ ==================================
Class of relevant security Ordinary Shares EUR0.01
to which the dealings each
being disclosed relate
(Note 2)
============================ ==================================
Date of dealing 9.1.12
============================ ==================================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following
dealing) in the class of relevant security dealt
in (Note 3)
================================================================
Long Short
============================ =============== =================
Number (%) Number (%)
============================ =============== =================
(1) Relevant securities 1,028,782
============================ =============== =================
(2) Derivatives (other
than options)
============================ =============== =================
(3) Options and agreements
to purchase/sell
============================ =============== =================
Total
============================ =============== =================
(b) Interests and short positions in relevant
securities of the company, other than the class
dealt in (Note 3)
================================================================
Class of relevant security: Long Short
============================ =============== =================
Number (%) Number (%)
============================ =============== =================
(1) Relevant securities
============================ =============== =================
(2) Derivatives (other
than options)
============================ =============== =================
(3) Options and agreements
to purchase/sell
============================ =============== =================
Total
============================ =============== =================
1 February 2009
3. DEALINGS (Note 4)
(a) Purchases and sales
================================================================================================================
Purchase/sale Number of relevant securities Price per unit
(Note 5)
============================ =================================================== =============================
s Sale 1,866,833 GBP0.07
============================ =================================================== =============================
(b) Derivatives transactions (other than options
transactions)
================================================================================================================
Product
name, e.g. Nature of transaction Number of relevant Price per
CFD securities unit
(Note 6)
(Note 7) (Note 5)
================== =============================== ======================================== =================
(c) Options transactions in respect of existing
relevant securities
(i) Writing, selling, purchasing or varying
================================================================================================================
Product Writing, Number of Exercise Type, Expiry Option
name, e.g. selling, securities price e.g. American, date money
call option purchasing, to which European paid/received
varying the option etc. per unit
etc. relates (Note (Note
7) 5)
============ ======================= ================ =========== ================= ======== =============
(ii) Exercising
================================================================================================================
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
============================ =================================================== =============================
(d) Other dealings (including transactions in
respect of new securities) (Note 4)
================================================================================================================
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
============================ =================================================== =============================
1 February 2009
4. OTHER INFORMATION
Agreements, arrangements or understandings relating
to options or derivatives
========================================================
Full details of any agreement, arrangement or
understanding between the person disclosing and
any other person relating to the voting rights
of any relevant securities under any option referred
to on this form or relating to the voting rights
or future acquisition or disposal of any relevant
securities to which any derivative referred to
on this form is referenced. If none, this should
be stated.
========================================================
Is a Supplemental Form 8 attached? (Note 9) NO
========================================================
Date of disclosure 9.1.12
================================= =====================
Contact name Paul Johnson
================================= =====================
Telephone number +44 (0) 1276 500618
================================= =====================
If a connected EFM, name
of offeree/offeror with
which connected
================================= =====================
If a connected EFM, state
nature of connection (Note
10)
================================= =====================
1 February 2009
This information is provided by RNS
The company news service from the London Stock Exchange
END
RETURVRRUNAAAAR
AGI (LSE:AGI)
Historical Stock Chart
From May 2024 to Jun 2024
AGI (LSE:AGI)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about AGI (London Stock Exchange): 0 recent articles
More AGI Therapeutics plc News Articles